TY - JOUR
T1 - A study on the morbid histopathological changes in COVID-19 patients with or without comorbidities using minimally invasive tissue sampling
AU - Goel, Ayush
AU - Ray, Animesh
AU - Chavan, Amitkumar
AU - Sahni, Shubham
AU - Gupta, Baidhnath K.
AU - Raut, Shrawan K.
AU - Agarwal, Shubham
AU - Nehra, Jagbir
AU - Somu, Bharadhan
AU - Raja, Ragu
AU - Aakansha,
AU - Nagpal, Chitrakshi
AU - Rajanna, Chaithra
AU - Shahi, Anand
AU - Rajendran, Anand
AU - Varadrajan, Ashwin
AU - Hasan, Inamul
AU - Choppala, Pratheek
AU - Priyadarshi, Megha
AU - Jain, Deepali
AU - Subramanian, Arulselvi
AU - Arava, Sudheer
AU - Singh, Geetika
AU - Das, Prasenjit
AU - Sarkar, Chitra
AU - Nischal, Neeraj
AU - Soneja, Manish
AU - Jorwal, Pankaj
AU - Trikha, Anjan
AU - Wig, Naveet
N1 - Publisher Copyright:
© 2022 Wiley Periodicals LLC.
PY - 2023/1
Y1 - 2023/1
N2 - COVID-19 causes morbid pathological changes in different organs including lungs, kidneys, liver, and so on, especially in those who succumb. Though clinical outcomes in those with comorbidities are known to be different from those without—not much is known about the differences at the histopathological level. To compare the morbid histopathological changes in COVID-19 patients between those who were immunocompromised (Gr 1), had a malignancy (Gr 2), or had cardiometabolic conditions (hypertension, diabetes, or coronary artery disease) (Gr 3), postmortem tissue sampling (minimally invasive tissue sampling [MITS]) was done from the lungs, kidney, heart, and liver using a biopsy gun within 2 hours of death. Routine (hematoxylin and eosin) and special staining (acid fast bacilli, silver methanamine, periodic acid schiff) was done besides immunohistochemistry. A total of 100 patients underwent MITS and data of 92 patients were included (immunocompromised: 27, malignancy: 18, cardiometabolic conditions: 71). In lung histopathology, capillary congestion was more in those with malignancy, while others like diffuse alveolar damage, microthrombi, pneumocyte hyperplasia, and so on, were equally distributed. In liver histopathology, architectural distortion was significantly different in immunocompromised; while steatosis, portal inflammation, Kupffer cell hypertrophy, and confluent necrosis were equally distributed. There was a trend towards higher acute tubular injury in those with cardiometabolic conditions as compared to the other groups. No significant histopathological difference in the heart was discerned. Certain histopathological features were markedly different in different groups (Gr 1, 2, and 3) of COVID-19 patients with fatal outcomes.
AB - COVID-19 causes morbid pathological changes in different organs including lungs, kidneys, liver, and so on, especially in those who succumb. Though clinical outcomes in those with comorbidities are known to be different from those without—not much is known about the differences at the histopathological level. To compare the morbid histopathological changes in COVID-19 patients between those who were immunocompromised (Gr 1), had a malignancy (Gr 2), or had cardiometabolic conditions (hypertension, diabetes, or coronary artery disease) (Gr 3), postmortem tissue sampling (minimally invasive tissue sampling [MITS]) was done from the lungs, kidney, heart, and liver using a biopsy gun within 2 hours of death. Routine (hematoxylin and eosin) and special staining (acid fast bacilli, silver methanamine, periodic acid schiff) was done besides immunohistochemistry. A total of 100 patients underwent MITS and data of 92 patients were included (immunocompromised: 27, malignancy: 18, cardiometabolic conditions: 71). In lung histopathology, capillary congestion was more in those with malignancy, while others like diffuse alveolar damage, microthrombi, pneumocyte hyperplasia, and so on, were equally distributed. In liver histopathology, architectural distortion was significantly different in immunocompromised; while steatosis, portal inflammation, Kupffer cell hypertrophy, and confluent necrosis were equally distributed. There was a trend towards higher acute tubular injury in those with cardiometabolic conditions as compared to the other groups. No significant histopathological difference in the heart was discerned. Certain histopathological features were markedly different in different groups (Gr 1, 2, and 3) of COVID-19 patients with fatal outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85145926571&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85145926571&partnerID=8YFLogxK
U2 - 10.1002/jmv.28384
DO - 10.1002/jmv.28384
M3 - Article
C2 - 36477876
AN - SCOPUS:85145926571
SN - 0146-6615
VL - 95
JO - Journal of Medical Virology
JF - Journal of Medical Virology
IS - 1
M1 - e28384
ER -